Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CTNNB1 act mut |
| Therapy | Tegavivint |
| Indication/Tumor Type | hepatocellular carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CTNNB1 act mut | hepatocellular carcinoma | predicted - sensitive | Tegavivint | Phase Ib/II | Actionable | In a Phase I/II trial, Tegavivint (BC2059) treatment was tolerated and demonstrated preliminary efficacy with 1 partial response (PR) and stable disease (SD) in 8 of 15 evaluable patients with advanced hepatocellular carcinoma, 6 of the 7 patients harboring CTNNB1 activation mutations achieved a best response of PR or SD, comparing to 3 in 8 of the CTNNB1 wild-type patients (Cancer Res (2025) 85 (8_Supplement_2): CT032; NCT05797805). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| Abstract CT032: Phase 1/2 trial of the TBL1 inhibitor, tegavivint, in advanced hepatocellular carcinoma (aHCC) | Full reference... |